Sorafenib in Advanced Hepatocellular Carcinoma

Spinzi, Giancarlo; Paggi, Silvia

doi:10.1056/nejmc081780

Cited by 53 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study was demonstrated for the first time that retinoblastoma protein (pRb2/p130) is inversely correlated with VEGF expression and tumor aggressiveness. VEGF together with pRb2/p130 may act a diagnostic or prognostic indicator in HCC [24, 53, 54]. …”

Section: Angiogenesismentioning

confidence: 99%

“…HCC tumour spread is partly dependent on neoangiogenesis [17, 54]. VEGF is considered one of the most important factors involved in neoangiogenesis, development and/or progression of HCC, being associated with a poor survival [50, 51, 53].…”

Section: Angiogenesismentioning

confidence: 99%

“…Oral multikinase inhibitor (e.g. Sorafenib, sunitinib) of the VEGF, PDGFR of downstream intracellular serine/threonine, is used with success in HCC therapy [17, 54]. …”

Section: Angiogenesismentioning

confidence: 99%

“…The Ang-2 gene is upregulated in the hypervascular type of HCC, being investigated in HCC [55]. Dominant Ang-2 expression against Ang-1 through Tie2 receptor in the presence of VEGF plays a critical role in initiating early neovascularization and transformation of noncancerous liver to HCC [53, 54, 55]. …”

Section: Angiogenesismentioning

confidence: 99%

See 3 more Smart Citations

Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers

et al. 2009

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignancies. Although many advances have been made in the clinical study of HCC, the prognosis remains poor. Despite the discoveries in cancer biology in respect with physiological and pathological factors in relation to prognosis, HCC remains still a fatal disease due to late diagnosis. For improving the outcomes of patients with HCC, it is important to identify the factors predisposing to patient death. In recent years, based on cellular and molecular biology techniques, many tumor markers related to invasion, metastasis, recurrence and survival have been explored. However, routine biomarkers for the prediction of HCC evolution and prognosis are available in small number and less specific. These reviews focus on the recent advances in HCC tumorigenesis, revealing those biomarkers with prognosis significance or can be used for early detection.

show abstract

Section: Angiogenesismentioning

confidence: 99%

Section: Angiogenesismentioning

confidence: 99%

“…Oral multikinase inhibitor (e.g. Sorafenib, sunitinib) of the VEGF, PDGFR of downstream intracellular serine/threonine, is used with success in HCC therapy [17, 54]. …”

Section: Angiogenesismentioning

confidence: 99%

Section: Angiogenesismentioning

confidence: 99%

See 2 more Smart Citations

Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers

et al. 2009

View full text Add to dashboard Cite

show abstract

“…These data are very promising, especially considering the overall poor prognosis of HCC patients. In the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) RR, survival rate at 12 months was 2% and 44%, respectively, and mOS was 10.7 months [89, 90]. Thus, a phase III study of nivolumab versus sorafenib in treatment-naïve patients has been planned and is already ongoing (CHECKMATE 459) [91].…”

Section: Focus On Hepatocellular Carcinomamentioning

confidence: 99%

Immunotherapy in Gastrointestinal Cancers

Procaccio

Schirripa

Fassan

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been reported, a strong biological rationale supports the development of immunotherapy in this field. The clinical and translational research on immunotherapy for the treatment of GI cancers started firstly with the identification of immune-related mechanisms possibly relevant to GI tumours and secondly with the development of immunotherapy-based agents in clinical trials. In the present review a general overview is firstly provided followed by a focus on major findings on gastric, colorectal, and hepatocellular carcinomas. Finally, pathological and molecular perspectives are provided since many efforts are ongoing in order to identify possible predictive biomarkers and to improve patients' selection. Many issues are still unsolved in this field; however, we strongly believe that immunotherapy might positively affect the natural history of a subgroup of GI cancer patients improving outcome and the overall quality of life.

show abstract

A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis

Xiao

Wang

Xiong

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Changes in immune responses to hepatocellular carcinoma (HCC) are closely related to the occurrence, development, and prognosis of this disease. Exploring the role of immune‐related genes (IRGs) in HCC would provide insights into the mechanisms regulating this disease. The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) provide a platform for such research, owing to a large number of HCC samples available for comprehensive and systematic immunogenomics analyses. We analyzed the IRGs expression profile and clinical information of patients with HCC based on the TCGA and ICGC database. Potential molecular mechanisms and properties of the screened IRGs were analyzed across multiple databases. And we analyzed the correlation between IRGs, single‐nucleotide polymorphisms, and copy number variation. A novel prognostic index, based on IRGs, was developed using the LASSO Cox regression algorithm, followed by univariate and multivariate Cox regression analyses to analyze the prognostic index. Information in the ICGC database was used to verify the reliability of the prognostic index. A total of 54 differentially expressed IRGs were found to be significantly associated with HCC prognosis, and there is a significant correlation between their expression level and copy number variation. Functional enrichment analyses indicated that the genes play active roles in tumor and immune‐related signaling pathways. In addition, five potential biomarkers namely IRG, MAPK3, HSP90AA1, HSP90AB1, HSPA4, and CDK4, were identified. Finally, a novel prognostic index, based on IRGs (PSMD14, FABP6, ISG20L2, HGF, BIRC5, IL17D, and STC2), was found useful as an independent prognostic factor, not only for prognosis but also to reflect levels of infiltration in a variety of immune cells. Our team conducted a genomics study of IRGs in HCC and screened several clinically significant IRGs, and our model provides an effective approach for stratification and characterization of patients using IRG‐based immunolabeling tools to monitor the prognosis of HCC.

show abstract

Sorafenib in Advanced Hepatocellular Carcinoma

Cited by 53 publications

References 15 publications

Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers

Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers

Immunotherapy in Gastrointestinal Cancers

A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis

Contact Info

Product

Resources

About